Consistent with previous studies of patients with NSCLC treated with PD-(L)1 blockade, we observed significant expansion of peripheral blood-activated CD8+ T cells in patients with tumors demonstrating MPR14–16. Here, CD8A is linked to non-small cell lung carcinoma.